26 May 2020 --- Hofseth BioCare (HBC) is entering into a Phase 2 clinical trial to assess the ability of OmeGo salmon oil to reduce Acute Respiratory Distress Syndrome (ARDS) related to COVID-19. HBC is currently preparing an investigational protocol with KGK Science, which will then be filed with Health Canada. The trial will use OmeGo in the form of CARDIO, a branded soft gel, on former smokers and steroid-resistant asthma patients who exhibit early non-acute lung injury caused by the SARS-CoV-2 virus. If the initial efficacy data is supportive, the trial can then be scaled to a fully powered Phase 3 study with 600 patients.
